NCT03155503View on ClinicalTrials.gov

A Study to Investigate the Safety, Tolerability and Pharmacokinetics of SUVN-911 in Healthy Subjects

PHASE1CompletedINTERVENTIONAL
Enrollment

64

Participants

Timeline

Start Date

May 22, 2017

Primary Completion Date

March 7, 2018

Study Completion Date

March 14, 2018

Conditions
Depressive Disorder, Major
Interventions
DRUG

SUVN-911

Oral Tablet

DRUG

Placebo

Oral Tablet

Trial Locations (1)

66211

QuintilesIMS Phase 1 Services, LLC, Kansas City

All Listed Sponsors
lead

Suven Life Sciences Limited

INDUSTRY

NCT03155503 - A Study to Investigate the Safety, Tolerability and Pharmacokinetics of SUVN-911 in Healthy Subjects | Biotech Hunter | Biotech Hunter